Cibus's Q1 2023 income from property management (IFPM) was below Infront consensus, even adjusted fo...
Ahead of Taaleri's Q1, due on 3 May, we maintain our underlying estimates but adjust for the IFRS 17...
Redeye retains its positive view of Hexatronic following a solid Q1 report, with EBITA beating our f...
Redeye återkommer med en update efter BioArctics Q1-rapport och ytterligare framsteg för Lecanemab.
Sales -4% vs. ABGSCe, EBITA -9% vs. ABGSCe Increased transparency on B3 Poland We expect cons.
Sales +12% vs ABGSCe, adj. EBITA +4% vs ABGSCe Soft near-term margin outlook, adj.
Redeye states that sales were in line with our expectations, while EBIT came in below our forecast.
Redeye states that Addnode had another solid quarter where sales and EBITA beat our forecasts.
Redeye comments on CI Games Q4'22 report, where sales came in line with our estimates while EBIT cam...
Redeye comments on AVTECH's Q1'23 report which was slightly below estimates on net sales while bette...
36% org. sales (ABGSCe 31%), 82% adj. EBIT growth Consensus 2023e EBIT could come up 5-10% Strong re...
Rovio reported Q1 revenue 2% below Modular Finance consensus and adjusted EBIT bang in line.
Redeye comments on Artificial Solutions Q1’23 report.
Q1 NOI 0% vs ABGSCe Property value changes -1.8% vs ABGSCe -1.
We raise '23e-'25e EBITA by ~3% Strong cash flow in Q1'23 Discussed discontinuation of unprofitable ...
Redeye retains its positive view of Efecte following a Q1 largely matching our forecasts.
CapMan reported Q1 EBIT of 0.5m, clearly below Refinitiv consensus.
Q1'23 report due on Tuesday, 9 May Revised oil price assumptions Reiterate fair value range of SEK 6...
Redeye returns with an update on Stille following its Q1 2023 report.
Redeye updates on Evolution post Q1-results which came in somewhat above our expectations driven by ...
